The newly released secondary endpoint data extends clinical evidence that intravenous Dyloject offers safe, efficacious and well-tolerated pain relief for abdominal and pelvic surgery, the company said.
Patient global evaluation scores and related measures of efficacy at 24 and 48 hours were statistically significantly higher than placebo for all three arms of the study: Dyloject 18.75mg and 37.5mg and the active comparator ketorolac 30mg. Compared to the ketorolac group, the Dyloject groups had a lower incidence of thrombophlebitis, and numerically fewer adverse events associated with postoperative bleeding, according to Javelin.